Neville Sanjana, PhD, is a core faculty member at the New York Genome Center and an assistant professor in the Departments of Biology and of Neuroscience and Physiology at New York University. He is holding a session at EO GLC’s Learning Day on 14 April 2019.
In the revolutionary field of gene editing, Dr. Sanjana’s work is among the most pioneering. At his New York City–based lab, Sanjana Lab, his team is applying genome engineering, molecular cloning, electrophysiology and imaging to grapple with the most challenging problems facing humankind today—including diseases such as cancer and infectious viral diseases.
In his GLC session, Dr. Sanjana will speak about the scientific frontiers in gene editing using a tool called CRISPR, which stands for clustered regularly interspaced short palindromic repeats. This name comes from CRISPR’s role in bacteria as an immune system to protect against viruses. CRISPR is also the common term for CRISPR-Cas9, a genetic engineering tool developed in 2012 that allows researchers to alter DNA sequences and adjust gene functionality.
“During my GLC presentation, I will explain how CRISPR is used to precisely modify genomes, including human genomes, and the broader implications of this new capability,” explains Dr. Sanjana. “CRISPR is the Model T of writing DNA: It has made a complicated process into something that is inexpensive, easy and accessible to biomedical researchers worldwide.”
GLC is EO’s flagship leadership event, offering unparalleled learning and networking opportunities. If you’re ready to take your entrepreneurial journey to the next level, explore the many benefits of EO membership.
While gene editing typically conjures visions of ethically questionable tailor-made tots—visions made tangible in 2018 news articles about He Jiankui—Dr. Sanjana’s work shows us that gene editing also holds the power to achieve greater good. Indeed, “this includes the ability to address pressing global problems, including food security through engineered plants, battling infectious diseases like malaria and creating new cellular therapies for cancer”—all of which are issues perfectly aligned with the UN Sustainable Development Goals, an initiative EO has pledged to support.
It’s his commitment to working toward a better future that makes bioengineer Neville Sanjana a perfect complement to GLC’s line-up of entrepreneurs and tech giants from around the globe.
To read more on Dr. Sanjana’s work with cancer treatment, check out this Time magazine article. For more on Dr. Sanjana’s perspective on today’s gene sequencing tools, read this article from Frontline Genomics magazine.